PARIS--(BUSINESS WIRE)--Regulatory News:
Market: Euronext Paris
Compartment: Compartment C
ISIN code: FR0012633360
|Date||Total number of shares(1)||Total number of voting rights|
voting rights (3)
|March 31, 2017||12,070,597||12,070,597||12,053,105|
(1) Including 45,000 new shares in accordance with the contract of Equity line financing concluded with Kepler Cheuvreux on 17th March 2017.
(2) The number of gross voting rights (or “theoretical” number of voting rights) serves as the basis for calculating the threshold crossings. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares carrying voting rights, including shares without voting rights.
(3) The number of net voting rights (or voting rights “exercisable at the General Assembly") is calculated without taking into account the shares with suspended voting rights. It is disclosed for the proper information of the general public, in accordance with the AMF recommendation dated July 17, 2007.
An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first mobile, connected, all-in-one diabetes management system that helps make life easier for patients. Compact, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real time. Cellnovo is currently participating in several major Artificial Pancreas projects with Diabeloop, TypeZero and Horizon 2020 to develop automated insulin delivery systems.
For further information please visit www.cellnovo.com
Cellnovo is listed on Euronext, Compartment C
ISIN: FR0012633360 – Ticker: CLNV